BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
March 27, 2002
View Archived Issues
Amrad’s Stock Falls On Poor Phase II Results For Emfilermin
Read More
New Gene Inhibition Technique Aims To Hasten Gene Analysis
Read More
Schering To Purchase Collateral For $140M In Stock Exchange
Read More
Millennium, Compugen In Deal For Protein Pathway Software
Read More
Cyclacel, University Of Edinburgh Form Drug Design Collaboration
Read More
Avidex Platform Creates TCRs; Company Planning Partnerships
Read More
U.S. Research Foundation Backs Swedish Stem Cell Program
Read More
ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s
Read More
Other News To Note
Read More
Vernalis Seeks Second Nasdaq Listing, Reports Profitability
Read More
J&J Buying Tibotec-Virco For $320 In Cash And Debt
PARIS Johnson & Johnson signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV for $320 million in cash and debt. (BioWorld International)
Read More